Efficacy of oral Granisetron in uremic pruritus
Authors
Abstract:
Background and aim: Uremic pruritus is a relatively common and distressing problem for patients with chronic renal failure. Serotonin and histamine have been reported as possible mediators of uremic pruritus. Granisetron, a potent and selective inhibitor of 5-HT3 receptors was developed for relief of chemotherapy induced nausea. There are some studies about effect of Ondansetron in uremic pruritus and recently one case report described relief of renal itch with Granisetron. The aim of our study was to evaluate the effect of Granisetron on uremic pruritus in patients with chronic renal failure under dialysis.Materials and methods: 14 uremic patients under hemodialysis with moderate and severe pruritus were enrolled in this open trial. Patients received Granisetron tablet (1 mg twice a day) for 1 month. Patients were asked to complete a questionnaire assessing the severity of pruritus on twice a day.Results: 77% of the patients responded to the treatment and on the 1st , 2nd and 4th weeks of treatment, the mean values of pruritus score were 23 (range 11-40), 16(range 8-35), 8(range 0-35) points, respectively, while at baseline (before treatment) it was 31 (range 20-35) points (p=0.03). Pruritus disappeared in 7 patients at the end of 4th week, and was mild in 3 others. This effect was maintained during the study. Weekly clinical and laboratory examinations showed no side effects.Conclusion: Granisetron may be an effective, safe and well tolerated drug for the treatment of uremic pruritus in hemodialysis patients.
similar resources
Effect of oral granisetron in uremic pruritus.
BACKGROUND Renal itch is a relatively common and distressing problem for patients with chronic renal failure. Granisetron, is a potent and selective inhibitor of 5-HT3 receptors. There have been some studies about the effect of ondansetron in uremic pruritus and one case report has recently described relief of renal itch with granisetron. AIMS To evaluate the effect of Granisetron on uremic p...
full textPregabalin and Uremic Pruritus
References 1. Khan TM, Aziz A, Suleiman AK. Effectiveness of posthemodialysis administration of pregabalin (75 mg) in treatment resistance uremia pruritus. J Pharm Bioallied Sci 2016;8:74‐6. 2. Rayner H, Baharani J, Smith S, Suresh V, Dasgupta I. Uraemic pruritus: Relief of itching by gabapentin and pregabalin. Nephron Clin Pract 2012;122:75‐9. 3. Shavit L, Grenader T, Lifschitz M, Slotki I. Us...
full textEffect of Sambucus ebulus topical preparation on uremic pruritus
Uremic pruritus is a common and distressing symptom that affects more than 40% of patients undergoing hemodialysis. Several medications as well as topical preparation have been used for relief this condition. Sambucus ebulus has been shown anti-inflammatory and wound healing effects. In this research, the antipruritic effect of S. ebulus fruit extract was evaluated on patients with uremic pruri...
full textAssessment of quality of life in hemodialysis patients with uremic pruritus from Iranian Medicine view
Background and Aim: Pruritus is one of the most common problems of chronic kidney diseases. Different treatment modalities, while extending the life span of patients, can lead to changes in their lifestyle, health status and ultimately change their quality of life (QOL). Understanding the different aspects of patients' QOL leads to better services provided by health care teams to improve the pa...
full textRecent Advances in Treatment for Uremic Pruritus
This review highlights recent advances in pathophysiology and treatment for uremic pruritus, especially focusing on various interventions. Pruritus in patients on hemodialysis (HD) and peritoneal dialysis (PD) still remains an unresolved issue. Recently, the efficacy and safety of nalfurafine hydrochloride have been reported in Japan, and at present, more than thirty thousand patients receive t...
full textMy Resources
Journal title
volume 10 issue 1
pages 20- 25
publication date 2007-04-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023